Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidant takes smaller heart failure device to US:

This article was originally published in Clinica

Executive Summary

The US FDA has approved Guidant's next-generation implantable device for treating heart failure - the CONTAK CD 2 cardiac resynchronisation therapy defibrillator (CRT-D). Measuring just 41cc, the physiologically shaped product is around 38% smaller than any competing CRT-D system in the US, claims the company. The device combines cardiac resynchronisation therapy with an implantable defibrillator to improve the quality of life for heart failure patients and protect them from sudden cardiac death.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts